Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination

Figures & data

Figure 1. Prognostic significance of plasma MMP-9, MPO, ARG1, and TGFβ in advanced BTC patients treated with PPV. To examine the prognostic significance of MMP-9, MPO, ARG1, and TGFβ in pre-vaccination plasma from advanced BTC patients treated with PPV (n = 25), curves for OS were estimated by the Kaplan-Meier method, and differences between survival curves were statistically analyzed using the log-rank test. Censored patients are shown as vertical bars. Patients treated with PPV were divided into 2 subgroups according to the median values of plasma MMP-9 (A), MPO (B), ARG1 (C), and TGFβ (D).

Table 1. Univariate and multivariate analyses with pre-vaccination clinical findings and laboratory data in BTC (n = 25)

	Univariate analysis		Multivariate analysis
Factor	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Hemoglobin (g/dl)	0.618 (0.392 – 0.976)	0.039
Albumin (g/dl)	0.158 (0.041 – 0.616)	0.008
IL-6 (pg/ml)	1.159 (1.055 – 1.274)	0.002	1.186 (1.058 – 1.327)	0.003
CRP (μg/ml)	1.533 (1.143 – 2.056)	0.004
Number of selected peptides	0.395 (0.163 – 0.953)	0.039	0.326 (0.124 – 0.856)	0.023
MMP-9 (mg/ml)	4.252 (1.647 – 10.975)	0.003	4.637 (1.670 – 12.877)	0.003
MPO (mg/ml)	2.080 (1.003 – 4.315)	0.049
ARG1 (μg/ml)	1.002 (0.993 – 1.011)	0.641
TGFβ (ng/ml)	0.741 (0.450 – 1.220)	0.239

Abbreviations: BTC, biliary tract cancer; CI, confidence interval; CRP, C-reactive protein; MPO, myeloperoxidase; ARG1, arginase 1

Figure 2. Prognostic significance of plasma MMP-9, MPO, ARG1, and TGFβ in advanced NSCLC patients treated with PPV. To examine the prognostic significance of MMP-9, MPO, ARG1, and TGFβ in pre-vaccination plasma from advanced NSCLC patients treated with PPV (n = 32), curves for OS were estimated by the Kaplan-Meier method, and differences between survival curves were statistically analyzed using the log-rank test. Censored patients are shown as vertical bars. Patients treated with PPV were divided into 2 subgroups according to the median values of plasma MMP-9 (A), MPO (B), ARG1 (C), and TGFβ (D).

Figure 3. Prognostic significance of plasma MMP-9 and MPO in advanced PC patients treated with PPV. To examine the prognostic significance of MMP-9 and MPO in pre-vaccination plasma from advanced PC patients treated with PPV (n = 41), curves for OS were estimated by the Kaplan-Meier method, and differences between survival curves were statistically analyzed using the log-rank test. Censored patients are shown as vertical bars. Patients treated with PPV were divided into 2 subgroups according to the median values of plasma MMP-9 (A) and MPO (B).